Opening Session Panel Discussion

First International Summit on Interventional Pharmacoeconomics

David A. Hyman, MD, JD, on Inclusive Shared Savings

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Issues in Oncology

Cost of Care

The ASCO Post Staff

Mark J. Ratain, MD, and Daniel Goldstein, MD, on Value in Cancer Care: How the Paradigm Is Shifting

Mark J. Ratain, MD, of the University of Chicago, and Daniel Goldstein, MD, of the Rabin Medical Center, discuss the challenges of achieving cancer care value, evolution of the “more-is-better” philosophy when it comes to oncology drugs, and highlights of the First International Summit on Interventional Pharmacoeconomics.

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Issues in Oncology

The ASCO Post Staff

Leonard B. Saltz, MD, on Interventional Pharmacoeconomics: A Pathway to Better Cancer Care

Leonard B. Saltz, MD, of Memorial Sloan Kettering Cancer Center, discusses interventional pharmacoeconomics as an important tool that can offer patients with cancer more efficacious and cost-effective care. Pharmacoeconomics may help reduce the high costs of cancer therapy, with evidence-based reductions in doses that maintain effective treatment.

Feb

Today In Oncology

Opening Session Panel Discussion

Related Videos

David A. Hyman, MD, JD, on Inclusive Shared Savings

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Mark J. Ratain, MD, and Daniel Goldstein, MD, on Value in Cancer Care: How the Paradigm Is Shifting

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Leonard B. Saltz, MD, on Interventional Pharmacoeconomics: A Pathway to Better Cancer Care

A New Risk Model for Esophagectomy Draws on the STS National Database

Olaparib in Metastatic Breast Cancer With Germline Mutations in PALB2 or Somatic Mutations in BRCA

Ultra–Low-Dose Immunotherapy in Relapsed or Refractory Solid Tumors

ASCO and Conexiant Launch ASCO AI in Oncology

Self-Acupressure May Ease Fatigue in Ovarian Cancer Survivors